Analysis
Solstice Oncology launched on September 9 with a $225 million Series A led by RA Capital Management, joined by Canaan Partners, Forbion and other investors, according to the company. The company, led by CEO Caroline Loew, is a spinout formed by Harbour BioMed alongside its venture backers, giving Solstice exclusive global rights to porustobart (also known as HBM4003), a second-generation, Fc-enhanced CTLA-4 antibody, in a deal FierceBiotech separately reported as worth up to $1.1 billion in biobucks to Harbour BioMed.
Founded in February 2026, Solstice is advancing porustobart in a Phase 2 trial combined with Merck's pembrolizumab (Keytruda) in the neoadjuvant setting for stage II-III microsatellite-stable colon cancer, plus a second, undisclosed indication; enrollment for the colon cancer trial opens in early Q4 2026. CTLA-4 inhibition is a validated but historically difficult mechanism -- Bristol Myers Squibb's ipilimumab (Yervoy) was the first approved CTLA-4 antibody in 2011, but the class has struggled with toxicity that has limited combination use, exactly the problem second-generation, Fc-enhanced antibodies like porustobart are designed to solve.
Solstice enters a crowded next-generation CTLA-4 field that includes Bristol Myers Squibb's own newer candidates and several biotechs pursuing similar Fc-engineering approaches to reduce toxicity while preserving efficacy -- a race where being second-generation is table stakes, not a differentiator, and clinical data, not funding size, will determine which asset actually reaches approval.
“The risk sits entirely in execution: porustobart hasn't generated Phase 2 data yet, and CTLA-4 combination toxicity has ended more promising programs than it's helped.”
A de-risked bet, not a platform bet
A $225 million Series A is large even by 2026 biotech standards, reflecting both the size of the licensing deal underlying it and RA Capital's willingness to write big first checks into de-risked, clinically-validated mechanisms rather than earlier-stage science. The risk sits entirely in execution: porustobart hasn't generated Phase 2 data yet, and CTLA-4 combination toxicity has ended more promising programs than it's helped.
Harbour BioMed, the Cayman Islands-incorporated, Nasdaq-and-Hong Kong-listed antibody company founded by Dr. Jingsong Wang, has increasingly used this spin-out model -- licensing a clinical-stage asset into a newly formed, separately capitalized company rather than running every program through its own balance sheet -- to bring more of its pipeline into the clinic without diluting its public shareholders on every program. RA Capital Management, one of the largest healthcare-focused investment firms, has a track record of anchoring similarly large first checks into de-risked, licensed assets rather than platform-stage science -- Pulse previously covered RA Capital anchoring a comparable early check into antibody-drug developer Infinimmune's $75 million Series A.
The exit math
The oncology M&A backdrop makes the math behind a $225 million bet more legible -- large pharma has kept paying premium prices for differentiated immuno-oncology assets with clean Phase 2 data:
- Bristol Myers Squibb -- acquired Karuna Therapeutics for $14B
- Solstice -- $225M Series A, plus $1.1B in potential biobucks owed to Harbour BioMed if porustobart succeeds
If porustobart's neoadjuvant colon-cancer data reads out well, Solstice becomes a plausible acquisition target for exactly the kind of large-cap oncology buyer that has paid double-digit-billion-dollar prices for comparable assets in the past two years; if the data disappoints, both figures become much harder to justify in hindsight.
The next concrete milestone for outside observers is enrollment completion and, eventually, an interim readout from the Phase 2 colon-cancer cohort -- until then, Solstice remains a bet on Harbour BioMed's prior antibody-engineering track record and RA Capital's underwriting discipline rather than on any Solstice-generated data of its own.
